Chemotherapy Induced Neutropenia – Pipeline Review, H2 2012

Publisher Name :
Date:26-Dec-2012
No. of pages: 87
Inquire Before Buying

Chemotherapy Induced Neutropenia – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, ‘Chemotherapy Induced Neutropenia – Pipeline Review, H2 2012′, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Neutropenia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Neutropenia. Chemotherapy Induced Neutropenia – Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Chemotherapy Induced Neutropenia.
- A review of the Chemotherapy Induced Neutropenia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Chemotherapy Induced Neutropenia pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Neutropenia.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Neutropenia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Chemotherapy Induced Neutropenia – Pipeline Review, H2 2012

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Chemotherapy Induced Neutropenia Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Chemotherapy Induced Neutropenia 10
Chemotherapy Induced Neutropenia Therapeutics under Development by Companies 12
Late Stage Products 15
Comparative Analysis 15
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Chemotherapy Induced Neutropenia Therapeutics - Products under Development by Companies 19
Companies Involved in Chemotherapy Induced Neutropenia Therapeutics Development 21
Kyowa Hakko Kirin Co., Ltd. 21
Dong-A Pharmaceutical Co., Ltd. 22
Maxygen, Inc. 23
Teva Pharmaceutical Industries Limited 24
Sandoz Inc. 25
Zosano Pharma, Inc. 26
LTT Bio-Pharma Co., Ltd. 27
Cellerant Therapeutics, Inc. 28
Med Discovery SA 29
Synageva BioPharma Corp. 30
Phage Biotechnology Corporation 31
Inimex Pharmaceuticals, Inc. 32
Bolder Biotechnology, Inc. 33
Welichem Biotech Inc. 34
USV Limited. 35
Pfenex Inc. 36
Eurofarma 37
Chemotherapy Induced Neutropenia - Therapeutics Assessment 38
Assessment by Monotherapy Products 38
Assessment by Combination Products 39
Assessment by Route of Administration 40
Assessment by Molecule Type 42
Drug Profiles 44
MAXY-G34 - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
MDPK-67b - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
Slow-Release G-CSF - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Pegylted GCSF - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
filgrastim - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
balugrastim - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
IMX-942 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
CLT-008 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
filgrastim - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
pegfilgrastim - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
pegfilgrastim - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
lipegfilgrastim - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
WBI-2100 + [cisplatin] - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
WBI-2100 + [gemcitabine hydrochloride] - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
WBI-2100 + [dacarbazine] - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
WBI-2100 + [paclitaxel] - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
TXA127 + Erythropoietin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
filgrastim - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
BBT-015 - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
BBT-018 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
IRX-4310 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
pegfilgrastim - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
filgrastim - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
filgrastim - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
filgrastim - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
F-627 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
F-627 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
filgrastim Biosimilar - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pegfilgrastim Biosimilar - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Chemotherapy Induced Neutropenia Therapeutics - Drug Profile Updates 75
Chemotherapy Induced Neutropenia Therapeutics - Discontinued Products 79
Chemotherapy Induced Neutropenia Therapeutics - Dormant Products 80
Chemotherapy Induced Neutropenia - Product Development Milestones 81
Featured News & Press Releases 81
Jun 29, 2012: Teva Pharma Provides Clinical Update On Balugrastim At MASCC/ISOO 2012 International Symposium On Supportive Care In Cancer 81
Jun 29, 2012: Teva Pharma Provides Clinical Update On Lipegfilgrastim At MASCC/ISOO 2012 International Symposium On Supportive Care In Cancer 81
Oct 10, 2011: Maxygen Announces Final Rejection Of All Claims Of Amgen ‘804 Patent In Inter Partes Reexamination Proceeding 82
May 31, 2011: Teva Announces Data On Granulocyte Colony Stimulating Factor Compounds For Prevention Of Chemotherapy-Induced Neutropenia In Breast Cancer Patients 82
May 31, 2011: Teva To Present Phase II Data Of Granulocyte Colony Stimulating Factor XM22 At ASCO 82
Mar 24, 2011: Telik Announces Preclinical Presentation At 102nd Annual Meeting Of American Association For Cancer Research 83
Mar 22, 2011: Cellerant Initiates Phase I/II Clinical Trial Of CLT-008 For Chemotherapy Induced Neutropenia In Acute Leukemia Patients 83
Nov 03, 2010: Bolder BioTechnology Announces $1.2 Million In Qualifying Therapeutic Discovery Project Grants 84
Dec 01, 2009: Teva Announces The Submission Of A Biologics License Application (BLA) For XM02 For The Treatment Of Chemotherapy-Induced Neutropenia 84
May 08, 2002: Amgen to Acquire Filgrastim and Pegfilgrastim in Europe from Roche 85
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87

List of Tables
Number of Products Under Development for Chemotherapy Induced Neutropenia, H2 2012 10
Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2012 11
Number of Products under Development by Companies, H2 2012 13
Number of Products under Development by Companies, H2 2012 (Contd..1) 14
Comparative Analysis by Late Stage Development, H2 2012 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Development by Companies, H2 2012 (Contd..1) 20
Kyowa Hakko Kirin Co., Ltd., H2 2012 21
Dong-A Pharmaceutical Co., Ltd., H2 2012 22
Maxygen, Inc., H2 2012 23
Teva Pharmaceutical Industries Limited, H2 2012 24
Sandoz Inc., H2 2012 25
Zosano Pharma, Inc., H2 2012 26
LTT Bio-Pharma Co., Ltd., H2 2012 27
Cellerant Therapeutics, Inc., H2 2012 28
Med Discovery SA, H2 2012 29
Synageva BioPharma Corp., H2 2012 30
Phage Biotechnology Corporation, H2 2012 31
Inimex Pharmaceuticals, Inc., H2 2012 32
Bolder Biotechnology, Inc., H2 2012 33
Welichem Biotech Inc., H2 2012 34
USV Limited., H2 2012 35
Pfenex Inc., H2 2012 36
Eurofarma, H2 2012 37
Assessment by Monotherapy Products, H2 2012 38
Assessment by Combination Products, H2 2012 39
Assessment by Stage and Route of Administration, H2 2012 41
Assessment by Stage and Molecule Type, H2 2012 43
Chemotherapy Induced Neutropenia Therapeutics - Drug Profile Updates 75
Chemotherapy Induced Neutropenia Therapeutics - Discontinued Products 79
Chemotherapy Induced Neutropenia Therapeutics - Dormant Products 80

List of Figures
Number of Products under Development for Chemotherapy Induced Neutropenia, H2 2012 10
Products under Development for Chemotherapy Induced Neutropenia - Comparative Analysis, H2 2012 11
Products under Development by Companies, H2 2012 12
Late Stage Products, H2 2012 15
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 38
Assessment by Combination Products, H2 2012 39
Assessment by Route of Administration, H2 2012 40
Assessment by Stage and Route of Administration, H2 2012 41
Assessment by Molecule Type, H2 2012 42
Assessment by Stage and Molecule Type, H2 2012 43

  • Challenges in the Tourism Industry in Thailand
    Thailand has always been a popular tourist destination and tourism provides a major boost to the country’s economy. Bangkok, Hua Hin, Krabi, Samui, Phuket and Cha Am are some of the most attractive tourist destinations in the country. In 2012, Thailand had a very high number of arrivals. Even the number of Thai citizens who [...]
  • Future of the US Consumer Electronics Market
    The market for consumer electronics has been growing steadily. Some of the factors that are contributing to the growth in the market are technological advancement, rise in disposable income and increasing demand for new products. During 2012, consumer electronics market in the US demonstrated positive expansion, although the growth rate slowed down considerably following the [...]
  • Overview of the Global Retail Market
    The global retail industry continued to grow despite the difficult economic conditions in the world. In the fiscal year of 2011, sales-weighted, currency-adjusted revenue rose by 5.1% to $4.271 trillion for the world’s top 250 retailers. According to GRDI (Global Retail Development Index), in 2013 Brazil occupied the top spot in retail development. Chile and [...]
  • Bright Future Predicted for the Tourism Industry in Singapore
    Travel and tourism industry in Singapore has been growing at a steady rate and is considered to be a major contributor to the economic growth of the country. In 2012, Singapore’s IVA (International Visitors Arrivals) reached a record high of 14.5 million, with a growth rate of 10.1% year-on-year. In recent years, inbound travel to [...]
  • Potential of Staffing Market in United States
    The staffing industry places individuals into contract, temporary and permanent positions in firms around the world. Major staffing markets include France, Spain, Italy and Japan as well as many emerging markets. Temporary staffing around the world has been growing, but in US temporary market has been flat since 2006. The majority of staffing revenue majorly [...]
  • Graft-Versus-Host Disease (GVHD) Treatment Market worth $407 million by 2018
  • The graft-versus-host disease (GVHD) treatment market value will increase from $297 million in 2013 to $407 million by 2018, at a Compound Annual Growth Rate (CAGR) of 6.59%, according to research and consulting firm GlobalData. The company’s latest report* states …

  • Poland Pharmaceutical Industry Growing at 8.3% CAGR to 2020
  • Factors such as the growing elderly population, increasing availability of affordable medicines, and transparent regulatory guidelines will provide the necessary impetus for the growth of the Polish pharmaceutical market, but a decrease in mark-up prices and the country’s stringent drug …

  • Asia-Pacific, Led by China, Drive the Global Methanol Industry
  • China is driving the global methanol industry, with tremendous demand from both its energy and petrochemicals sectors. It accounts for 87.9% of Asia-Pacific’s (APAC) methanol capacity, and 51.9% of the global methanol capacity. Despite a large planned capacity increase in …

  • Diagnostic X-ray Imaging Market worth $4.0 billion by 2020
  • GlobalData estimates that the global diagnostic X-ray imaging market, worth $2.4 billion in 2012, will reach almost $4.0 billion by 2020, increasing at a Compound Annual Growth Rate (CAGR) of 6.7% during the forecast period. Many players are active in …

  • Graft-Versus-Host Disease Market Forecast to 2023
  • Graft-versus-host disease (GVHD) is a common complication of allogeneic hematopoietic stem cell transplantation (HSCT) that occurs when the donated (graft) cells are rejected and attack the host’s cells as foreign. GVHD can progress from mild to severe forms as either …

  • EpiCast Report: Breast Cancer (HER2-, HER2+) – Epidemiology Forecast to 2023
    Published: 10-Sep-2014        Price: US $3995 Onwards        Pages: 70
    Breast cancer is a malignant tumor that originates in the breast tissues. Most breast cancers are invasive tumors that have grown beyond the ducts or lobules of the breast and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Prolonged exposure to endogenous and exogenous sex hormones, gene mutations, a family history of breast cancer, overweight and obesity, physical inactivity, a sedentary lifestyle, high alcohol consumption, early age at menarche (&l......
  • Global Non-small Cell Lung Cancer Market 2014-2018
    Published: 10-Sep-2014        Price: US $2500 Onwards        Pages: 92
    Non-small cell lung cancer occurs when normal cells grow and multiply without control after undergoing a cell transformation. Lung cancer is the leading cause of cancer deaths worldwide, and the incidence of lung cancer is increasing significantly. Lung cancer is the common cause of mortality and morbidity not only in developed countries but also in developing countries. One of the most common types of lung cancer is non-small cell lung cancer. It grows and spreads quite slowly. Smoking is consi......
  • Burkitt Lymphoma – Pipeline Review, H2 2014
    Published: 10-Sep-2014        Price: US $2000 Onwards        Pages: 47
    Burkitt Lymphoma - Pipeline Review, H2 2014SummaryGlobal Markets Direct's, ‘Burkitt Lymphoma - Pipeline Review, H2 2014', provides an overview of the Burkitt Lymphoma's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Burkitt Lymphoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and fe......
  • Uterine Cancer – Pipeline Review, H2 2014
    Published: 10-Sep-2014        Price: US $2000 Onwards        Pages: 66
    Uterine Cancer - Pipeline Review, H2 2014SummaryGlobal Markets Direct's, ‘Uterine Cancer - Pipeline Review, H2 2014', provides an overview of the Uterine Cancer's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Uterine Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured n......
  • Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) – Pipeline Review, H2 2014
    Published: 31-Aug-2014        Price: US $2000 Onwards        Pages: 538
    Global Markets Direct's, ‘Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Review, H2 2014', provides an overview of the Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia)'s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA)......
  • Cervical Cancer – Pipeline Review, H2 2014
    Published: 31-Aug-2014        Price: US $2000 Onwards        Pages: 236
    Global Markets Direct's, ‘Cervical Cancer Pipeline Review, H2 2014', provides an overview of the Cervical Cancer's therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Cervical Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key playe......
  • EpiCast Report: Renal Cell Carcinoma – Epidemiology Forecast to 2023
    Published: 25-Aug-2014        Price: US $3995 Onwards        Pages: 43
    EpiCast Report: Renal Cell Carcinoma - Epidemiology Forecast to 2023SummaryRenal cell carcinoma (RCC) is a type of kidney cancer that originates in the lining of the proximal convoluted tubule, a part of the very small tubes in the kidney that transport waste molecules from the blood to the urine. The condition is asymptomatic in its initial stages, and as a result, people with RCC are often in the advanced stages of the disease by the time it is discovered. The initial symptoms of RCC o......
  • OpportunityAnalyzer: Non-Hodgkin’s B-Cell Lymphoma – Opportunity Analysis and Forecast to 2018
    Published: 25-Aug-2014        Price: US $7995 Onwards        Pages: 178
    OpportunityAnalyzer: Non-Hodgkin's B-Cell Lymphoma - Opportunity Analysis and Forecast to 2018SummaryThe competitive landscape in the B-cell NHL markets in the US, France, Italy, Germany, Spain and the UK is poised to undergo a dramatic shift during the forecast period. Disease management of the four largest B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Marginal Zone Lymphoma (MZL), and Mantle Cell Lymphoma (MCL), currently revolv......
  • Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 – Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM
    Published: 20-Aug-2014        Price: US $4995 Onwards        Pages: 105
    GBI Research, the leading business intelligence provider, has released its latest research, ""Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel Therapeutic Approaches Target High Unmet Need in Newly Diagnosed and Recurrent GBM"", which provides in-depth analysis of the Glioblastoma Multiforme (GBM) therapeutics market within the Asia-Pacific (APAC) region, covering Australia, China, India and Japan. The report provides estimates of market size for 2013, along with mark......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs